V. Meiffrédy

发表

Effect of Zidovudine Resistance Mutations on Virologic Response to Treatment With Zidovudine or Stavudine, Each in Combination With Lamivudine and Indinavir

F. Brun-Vézinet, J. Izopet, G. Peytavin, 2002, Journal of acquired immune deficiency syndromes.

Adverse Reactions to Cotrimoxazole in HIV-infected Patients: Predictive Factors and Subsequent HIV Disease Progression

F. Raffi, C. Leport, P. Yeni, 2001, Scandinavian journal of infectious diseases.

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial

D. Cooper, J. Darbyshire, B. Salzberger, 2006, The Lancet.

Hyperlactataemia in HIV‐infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial)

D. Cooper, P. Yeni, R. Goodall, 2011, HIV medicine.

Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients

A. Samri, B. Autran, O. Launay, 2018, AIDS.

Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial.

B. Autran, E. Morelon, D. Bottigioli, 2012, Vaccine.

Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals

C. Rouzioux, M. Kazatchkine, Y. Lévy, 2006, AIDS.

Incidence and Risk Factors of Thrombocytopenia in Patients Receiving Intermittent Antiretroviral Therapy: A Substudy of the ANRS 106-Window Trial

C. Katlama, P. Bierling, P. Morlat, 2009, Journal of acquired immune deficiency syndromes.

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

V. Calvez, F. Brun-Vézinet, C. Delaugerre, 2000, JAMA.

Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

P. Yeni, V. Joly, P. Flandre, 2002, AIDS.

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.

F. Brun-Vézinet, F. Raffi, G. Pialoux, 1998, The New England journal of medicine.

Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults

Y. Lévy, J. Guillet, O. Launay, 2006, AIDS.

Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients

C. Rouzioux, Y. Lévy, J. Guillet, 2005, AIDS.

A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients.

F. Brun-Vézinet, J. Izopet, C. Tamalet, 2004, The Journal of infectious diseases.

Predictive Factors and Selection of Thymidine Analogue Mutations by Nucleoside Reverse Transcriptase Inhibitors According to Initial Regimen Received

F. Brun-Vézinet, J. Izopet, C. Tamalet, 2003, Antiviral therapy.

Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study.

C. Rouzioux, Y. Lévy, R. El Habib, 2007, AIDS research and human retroviruses.

Final analysis of the Trilège induction-maintenance trial: results at 18 months

V. Calvez, F. Raffi, G. Peytavin, 2002, AIDS.

Efficacy of Zidovudine Compared to Stavudine, Both in Combination with Lamivudine and Indinavir, in Human Immunodeficiency Virus-Infected Nucleoside-Experienced Patients with No Prior Exposure to Lamivudine, Stavudine, or Protease Inhibitors (Novavir Trial)

F. Brun-Vézinet, D. Descamps, C. Goujard, 2002, Antimicrobial Agents and Chemotherapy.

CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART

F. Brun-Vézinet, D. Scott‐Algara, F. Raffi, 2001, Clinical and experimental immunology.

Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.

P. Morlat, C. Rouzioux, L. Meyer, 2022, The Journal of antimicrobial chemotherapy.

Adherence to Antiretroviral Therapy and Outcomes in HIV-Infected Patients Enrolled in An Induction/Maintenance Randomized Trial

F. Brun-Vézinet, F. Raffi, G. Peytavin, 2001, Antiviral therapy.

A 5-year neutralizing immune response to yellow fever vaccine in HIV-infected and HIV-uninfected adults

A. Samri, B. Autran, O. Launay, 2022, AIDS.

Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype

R. Césaire, A. Amara, J. Molina, 2017, PloS one.

Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).

Philippe Flandre, Françoise Brun-Vézinet, Diane Descamps, 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.